YOUR BUSINESS AUTHORITY
Springfield, MO
Pfizer Inc. is considering a merger of its off-patent drug business with generic drugmaker Mylan, people familiar with the matter told The Wall Street Journal.
Under the proposal, Mylan shareholders would own more than 40% of the new entity and Pfizer shareholders would own the remainder.
Such a deal would create a global company that sells lower-priced pharmaceuticals.
Read more from The Wall Street Journal.
Organizers hope to bolster client traffic to center city businesses.